trastuzumab emtansine
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
... as trastuzumab, lapatinib, trastuzumab emtansine (T-DM1), and pertuzumab, are standard agents in the treatment of breast cancer overexpressing the human epidermal growth factor receptor 2 ...(HER2). ...
5
Relationship between HER2 expression and efficacy with first line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2 positive metastatic breast cancer
... HT, trastuzumab plus docetaxel; max, maximum; min, minimum; T-DM1, trastuzumab ...to trastuzumab plus docetaxel was estimated by logistic ...the trastuzumab plus docetaxel ...
10
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
... of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer; HER, human growth factor receptor; MBC, ...
10
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
... prognosis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that results from the combination of trastuzumab and DM1, a derivative of the antimicrotubule agent ...T-DM1, trastuzumab ...
9
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
... of combining osimertinib with trastuzumab emtansine (T-DM1) in order to improve the efficacy of osimertinib and delay or overcome resistance in NSCLC cell lines with EGFR activating muta[r] ...
12
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
... Abstract: Trastuzumab is a monoclonal antibody that is used in the treatment of breast ...cancer. Trastuzumab targets the human epidermal growth factor receptor 2 (HER2) receptor on breast cancer cells that ...
11
Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
... I. Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the ...
19
Phase 1b/2a study of trastuzumab emtansine (T DM1), paclitaxel, and pertuzumab in HER2 positive metastatic breast cancer
... toxicity; ECOG: Eastern Cooperative Oncology Group; ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; HR: Hazard ratio; LABC: Locally advanced breast cancer; LC-MS/MS: Liquid chromatography- tandem ...
10
A randomized, controlled phase II trial of neoadjuvant ado trastuzumab emtansine, lapatinib, and nab paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2 positive breast cancer (TEAL study)
... Previously, we completed a dose-finding trial of T- DM1, lapatinib, and nab-paclitaxel which yielded a high objective response rate as well as complete responses in heavily pretreated metastatic HER2-positive breast ...
9
Trastuzumab emtansine: mechanisms of action and drug resistance
... of trastuzumab in ...after trastuzumab-based therapy [7]. As to trastuzumab, resis- tance to lapatinib develops frequently among patients who initially respond ...with trastuzumab and ...
12
Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
... (“trastuzumab emtansine” or “T-DM1” or “trastuzumab-DM1”) and “HER2” and (“breast cancer” or “metastatic breast cancer”) and clinical trial, with- out language or time ...(“trastuzumab ...
18
A review of survival analysis methods used in NICE technology appraisals of cancer treatments : consistency, limitations and areas for improvement
... [43] NICE TA371 / TA458 Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane accessed[r] ...
19
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
... ado-trastuzumab emtansine; HRG: heregulin; HER2Bi- aATC: HER2-targeted bispecific antibody armed activated T cell; FDA: Food and Drug Administration; PFS: progression-free survival; CBR: clinical benefit ...
15
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2 positive breast cancer
... ado-trastuzumab emtansine, where the treatment benefit was similar for patients with wild-type and mutant ...ado- trastuzumab emtansine can overcome the impact of PIK3CA mutation on outcome, ...
12
<p>Current Molecular Targeted Agents for Advanced Gastric Cancer</p>
... that trastuzumab plus chemother- apy substantially increased OS (median overall survival 16·0 months) in patients with HER2 ...agent trastuzumab and chemother- apy agents for patients with HER2 ...received ...
14
Strategy for treatment of stage IV human epidermal growth factor 2 positive gastric cancer: a case report
... after surgery remain unclear. In this case, we selected DCS regimens as an induction chemotherapy and did not check HER2 status, because we planned conversion surgery and DCS showed a better response rate (RR, 81%) than ...
6
Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
... antibody trastuzumab, and its approval in 1998 for the treatment of patients with metastatic disease, radically changed the natural history of this aggressive subtype of breast ...Besides trastuzumab, a ...
10
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis
... CD47 blockade increases therapeutic efficacy of 4D5 and augments TAM expansion and phagocytosis. Our find- ings strongly supported an ADCP MOA for trastuzumab antitumor efficacy, which suggests that strategies to ...
22
An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
... H2-18, trastuzumab and pertuzumab binds different domains of ...in trastuzumab-resistant breast cancer cells ...in trastuzumab-sensitive breast cancer cells, but also in trastuzumab-resistant ...
13
Prediction of key genes and pathways involved in trastuzumab resistant gastric cancer
... one trastuzumab-sensitive NCI-N87 cell line and four trastuzumab-resistant cell lines (N87-TR1, N87-TR2, N87-TR3, ...The trastuzumab treatments were stopped when the tumors were ...four ...
12